DIVING, BOATING, FISHING,
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I THINK HTDS IS great, BECAUSE, I bought @.0009 and sold @.0043, THEN I bought @.005 and sold @.02..I THINK htds is because they MAKE MONEY for MY acount..Regards,CaptD.
The 'whole' MONA family is making noise..End Q3 is nearing too.
Those that make money, those that 'don't'??..I'm pleased with turning a fliped for profit, and a 'free ride'.
GLTY...MONA, play the play!! there's money to be made on MONA.
"free ride' is goood toooo.....
MONAmoney AND strong hands..The only way to win??
MONAmoney, is good for some, and surely NOT EVERYONE. PINK STOCKS REQUIRE strong hands. I'm happy with MONA..Regards,CaptD.
I SEE Scott and Company value the R/V Deep Scan, @$450,000.oo, acounting from their web-site,"filings" www.rsoperations.com/
"i can't go for that'?.Regards,CaptD.(smells fishy)
THIS IS INFORMATIVE??Regards,CaptD.
Oceanic Research and Recovery, Inc. (ORR) is a marine research and artifact recovery company. It is organized under the laws of the State of Nevada. ORR has its corporate office in Lindon, UT and its base of operations is in Key West Florida. ORR owns 3 research and recovery vessels and maintains an office and warehouse in Key West.
ORR owns survey and recovery permits for approximately 25 square miles of marine area, with the rights to research and salvage any materials from this site. ORR is presently conducting its operations and intends to continue through the 2008 dive season.
THEY RETIRED THE IDEA OF RASING MONEY THAT WAS...period...
SHOW ME THAT IN TEXT, because that IS NOT what the filing says..The filing says they RETIRED that idea...
WRONG AGAIN.!!!..EX THE OPPSITE..RETIRED!!! the idea..READ THE WHOLE DOC.Hard To Treat Diseases (HTDS) to Retire Regulation D 504 Offering
SHENZHEN, China, Sept 03, 2009 /PRNewswire-FirstCall via COMTEX/ -- Hard to Treat Diseases (the "Company") (HTDS.PK) announced today that it has closed its Regulation D, Rule 504 offering and is no longer selling shares of its common stock to accredited investors. A Form D will be filed with the Securities and Exchange Commission shortly, disclosing that the company has raised $990,000 in the offering over the past twelve months. The limit to any such offering is $1 million per year.
HTDS is a holding company for China-based Shenzhen Mellow Hope Pharm Industrial Co., Ltd. Mellow Hope is the biggest exporter of biological vaccines in China. Based on the cooperation with Institutes of Medical Biology and pharmaceutical manufacturers, Mellow Hope provides a wide range of vaccines with high quality, safety and efficacy. HTDS' other controlling interests include an East European (Serbian) medical company, Slavica Biochem, whose experts are performing cutting edge research in the field of neurological impairments in Multiple Sclerosis (MS) a nd Traumatic Brain Injury (TBI). The primary focus of Slavica Biochem is to investigate novel therapeutic approaches in treatment of these disorders of the CNS (central nervous system), as well as to enhance and modify existing approved drugs such as VIRAZOLE(R).
Closing the 504 offering brings to an end the issuer's recent use of equity in financing operations. With the new increased pool of credit the issuer intends to cover a majority of its upfront costs associated with its increasing contract demands. The issuer is looking forward to releasing quite a bit of new information over the next few weeks, including the finalized contracts as well as outlining its revised business plan to shareholders and potential investors. The revised business plan under consideration includes an anti-aging and cancer treatment project through nutritional supplementation.
The equity in financing has also opened up an opportunity for HTDS management to explore a possible lucrative joint venture project with a North American-based pharmaceutical company.
The issuer does not foresee the need or reason to disturb its current share structure, through dilution or otherwise. Management now intends to recalibrate its focus to its previously announced plans of addressing its share price, and matters that will increase its shareholder value. The issuer remains very optimistic that a 0.03 cent price per share is within its reach.
The issuer intends to furnish its shareholders with forward guidance shortly.
Safe Harbor Statement:
Very sincerely, RS Operations Team:Regards,CaptD.
PUT ME ON. I didn't beg a job?????..I said I'd do ANYTHING to help....with phone calls, e-mails, ect..ONLY Gerry, had an open line. I went to Peoria to talk...???.oh well. I went to KeyWest, oh well...NO RESPONDS...NO WHERE..BUT HERE & Gerry..
HTDS is a ?new? company,Regards,CaptD.
ONLY 'strongHANDS' .....!!..GLTY..
HEAR IT HERE FIRST. REgards,CaptD.
News for 'HTDS' - (Hard To Treat Diseases (HTDS) to Retire Regulation D 504 Offering)
SHENZHEN, China, Sept 03, 2009 /PRNewswire-FirstCall via COMTEX/ -- Hard to
Treat Diseases (the "Company") (HTDS.PK) announced today that it has closed its
Regulation D, Rule 504 offering and is no longer selling shares of its common
stock to accredited investors. A Form D will be filed with the Securities and
Exchange Commission shortly, disclosing that the company has raised $990,000 in
the offering over the past twelve months. The limit to any such offering is $1
million per year.
HTDS is a holding company for China-based Shenzhen Mellow Hope Pharm Industrial
Co., Ltd. Mellow Hope is the biggest exporter of biological vaccines in China.
Based on the cooperation with Institutes of Medical Biology and pharmaceutical
manufacturers, Mellow Hope provides a wide range of vaccines with high quality,
safety and efficacy. HTDS' other controlling interests include an East European
(Serbian) medical company, Slavica Biochem, whose experts are performing cutting
edge research in the field of neurological impairments in Multiple Sclerosis
(MS) and Traumatic Brain Injury (TBI). The primary focus of Slavica Biochem is
to investigate novel therapeutic approaches in treatment of these disorders of
the CNS (central nervous system), as well as to enhance and modify existing
approved drugs such as VIRAZOLE(R).
Closing the 504 offering brings to an end the issuer's recent use of equity in
financing operations. With the new increased pool of credit the issuer intends
to cover a majority of its upfront costs associated with its increasing contract
demands. The issuer is looking forward to releasing quite a bit of new
information over the next few weeks, including the finalized contracts as well
as outlining its revised business plan to shareholders and potential investors.
The revised business plan under consideration includes an anti-aging and cancer
treatment project through nutritional supplementation.
The equity in financing has also opened up an opportunity for HTDS management to
explore a possible lucrative joint venture project with a North American-based
pharmaceutical company.
The issuer does not foresee the need or reason to disturb its current share
structure, through dilution or otherwise. Management now intends to recalibrate
its focus to its previously announced plans of addressing its share price, and
matters that will increase its shareholder value. The issuer remains very
optimistic that a 0.03 cent price per share is within its reach.
The issuer intends to furnish its shareholders with forward guidance shortly.
Safe Harbor Statement
I have done my best for DD on the company. The fact CaptX and I are friends, is here nor there. I was ASKED to go to Equador two years ago, and declined!!! I was at one time interested in being a part of this HUNT. Due to My DD and research, I don't think I can, in good faith travel, to who knows where and have to fight to get paid. It's odd, that EVERYONE I have talked with, that has worked for this company, is NOT HAPPY with their employment there. Two/three of them are still not paid? (and I'm full of B.S.)ALTHOUGH, I've been to Bayou LaBatre, AL. and Peoria,IL, and KeyWest/Stock Island, to seek the truths as of what was and what is concerning my investment. I have only some 'stock' as intrest today.(that I can't sell but for a loss.)I will continue to track ANY and ALL information I can, and REPORT BACK to this stock board for ORRV, as to MY findings. AGAIN, anyone from the corporation side is WELCOME to challange my findings if one feels I'm not truthful/accurate. Regards,CaptD.IMOofcourse!!
ALL BE IT, ORRV, may recover? it doesn't sound good yet.IMO, CaptD.
At no time was Mr Berrier ever offered a job. This is a total fabrication.(said Mr. Gruby)
DOES ANY OF THIS SOUND RIGHT TODAY?
===============================================================
To: captaind2u@xxxxxx.com
Date: Friday, April 24, 2009, 11:52 AM
I am extremely pleased to see that you will be the captain. I look forward to working with you as I am the field operations manager for RSOPS.
Sincerely Gerry Edwards "Grubby"
===============================================================
BEWARE.!!. I TOO SAVE 'EVERY' e-mail, communication, filing for companys I follow/invest in.
FYI, & IMO, BUY while they are cheep..Regards,CaptD.
Q4 filings and into 2010, some age on the company and 'acounts due', should prove very interesting.
RMDM: I see much progress in the past year.Looking foreward I see better days to come.Regards,CaptD.:
RMD Entertainment Group (RMDM) (Filing)
Beijing China March 6 ,2OO9 - RMD Entertainment Group (RMDM:PK) (www.rmdmgroup.com) is
providing the following filing on Pink Sheets as an update on the status of its anticipated reverse stock
split. Although parts of this report may or may not be newsworthy, the Company is providing this
information that it feels may be of interest to its shareholders.
On December 1, 2008, FINRA (Financial Industry Regulatory Authority) implemented a new policy for
effectuating corporate actions for an OTCBB quoted or OTC traded security. (Securities traded on the
Pink Sheet only are considered OTC securities.) In addition to a cover letter and certain legal documents,
the procedure now requires the attached standardized forms be completed. These forms are required to
be completed in their entirety and must be submitted to the Corporate Data Operations Department.
The Company’s Transfer Agent has reported that an initial review of documentation submitted in regards
to a reverse stock split and other related corporate actions has been completed by the NASD and FINRA.
There are a number of additional items to be filed, that includes:
• FINRA OTC Equity Issuer Notification Form
• OTC Equity Name Change / Stock Split Request
• Various signed consent forms and notarized copies of resolutions related to the requested
actions.
• Activities documentation for Giogio Costanis and Mark Davis.
The Company will be working with its Transfer Agent to provide all of the requested documentation in a
timely fashion, including the adequate disclosure for Pink Sheets.com
The Company has also been advised that there is a significant backload of mergers, acquisitions,
recapitalizations etc. that are currently under review by FINRA and NASD, and there may be some delays
as the regulatory bodies conduct all of the necessary review of these applications. The requisite items
must be received, reviewed and verified before a date can be determined for effectiveness in the
marketplace.
Safe Harbor statement under the Private Securities Litigation Reform Act of 1995: Certain forward
information contained in this release contains forward-looking statements that involve risk and
uncertainties, including but not limited to, those relating to development and expansion activities,
domestic and global conditions, and market competition.
Get the Facts Right. The issuer works hard to continue to keep our shareholders informed, and news is
updated frequently via Press Releases, Pink Sheet http://www.pinksheets.com/ filings, and updates to our
websites. Other websites not sponsored, or recognized by the Company may provide misleading or
disinformation to investors in order to manipulate trading patterns for a given stock. Always look for
original content from trusted sources, rather than relying on 'excerpts' or discussion boards that may not
give you the whole story. The Securities and Exchange Commission requires financial institutions or
brokerage firms to provide their clients with documentation, describing the risks of investing in penny
stocks.
CONTACT: corporate@rmdmgroup.com
It will be a great time to go hunting ? "after the storm"?..
Regards,CaptD.(THE s.e. Beach.......?????
LOOKS TO BE 'ROUGH & WET'Regards,CaptD.
LOOKS LIKE STORMY WEATHER COMMING:Regards,CaptD.
LOOKS LIKE 'STORMY' WEATHER COMMING?Regards,CaptD.
EQUADOR
SEE 'HISTORY' CHANNEL 127 treasures@ 5:00EST.
HERE.!. is what real treasure looks like.Regards,CaptD.
News for 'HTDS' - (Hard To Treat Diseases (HTDS.PK) Stem Cells and Regenerative Medicine)
PIRAN, Slovenia/BELGRADE, Serbia, Sep 01, 2009 (PR Newswire Europe via COMTEX)
-- Hard To Treat Diseases (HTDS.PK) financed the participation of Dr. Ivana
Gadjanski in the International Summer School for Stem Cells and Regenerative
Medicine held in Piran, Slovenia (21-29. Aug 2009) where a number of eminent
speakers presented their work. Among them were Dr. Stephen Minger from King's
College, London; Dr. Smadar Cohen from Ben-Gurion University of the Negev,
Israel; Dr. Thomas Ekstrom from Karolinska Institute, Stockholm, Sweden; Dr.
Zoran Ivanovic from EFS, Bordeaux, France; Dr. Dasa Cziskova from Institute of
Neurobiology, Kosice, Slovakia, Dr. Tanja Dominko and Dr. Raymond L. Page from
Worcester Polytechnic Institute, USA, Dr. Darja Marolt from Columbia University,
USA. Several main topics were discussed: stem cell sources most suitable for
clinical application, ethical issues related to stem cell use, obstacles of stem
cell therapy (e.g. teratoma formation), future clinical trials (the most
interest evokes the FDA-approved world's first human clinical trial of an
embryonic stem cell-based therapy for acute spinal cord injury which will be
perfomed by Geron using their human embrionic stem cell-derived oligodendrocytes
GRNOPC1. The Investigational New Drug Application is currently on clinical hold
by the FDA pending the agency's review of new nonclinical animal study data
submitted by the company. More information availaible from
http://www.geron.com/patients/clinicaltrials/hESC.aspx). Also more technical
issues were discussed, e.g. types of biomaterials used for scaffolds, types of
bioreactors for growing cells, protocols for cell isolation from various
tissues, ways of inducing pluripotency in somatic stem cells (producing iPS),
using umbilical cord blood as a source of stem cells. Very promising are
adipose-derived stem cells (APC), where first reports are available on the in
vivo bone formation and bone augmentation using APC. This type of stem cells
raises the least ethical issues and might hold the highest potential for
clinical application. However, the takehome message of the whole symposium was
that the major task should be to stimulate endogenous potential for repair
rather than to force usage of stem cell therapy per se.
The company intends to provide further updates on a timely basis.
AS OF TODAY, PS.COM ..Regards,CaptD.
http://www.pinksheets.com/pink/quote/quote.jsp?symbol=ORRV
AS OF TODAY?Regards,CaptD.
OCEANIC RESEARCH & RECOVERY, INC.
Business Entity Information
Status: Default File Date: 2/6/2004
Type: Domestic Corporation Corp Number: C2969-2004
Qualifying State: NV List of Officers Due: 2/28/2009
Managed By: Expiration Date:
Registered Agent Information
Name: THE CORPORATION TRUST COMPANY OF NEVADA Address 1: 6100 NEIL ROAD SUITE 500
Address 2: City: RENO
State: NV Zip Code: 89511
Phone: Fax:
Mailing Address 1: Mailing Address 2:
Mailing City: Mailing State: NV
Mailing Zip Code:
Agent Type: Commercial Registered Agent - Corporation
Jurisdiction: NEVADA Status: Active
View all business entities under this registered agent
Financial Information
No Par Share Count: 0 Capital Amount: $ 77,500.00
Par Share Count: 750,000,000.00 Par Share Value: $ 0.0001
Par Share Count: 25,000,000.00 Par Share Value: $ 0.0001
Officers Include Inactive Officers
Secretary - BRETT CLINGER
Address 1: 1464 W 40 S Address 2:
City: LINDON State: UT
Zip Code: 84042 Country: USA
Status: Active Email:
Treasurer - BRETT CLINGER
Address 1: 1464 W 40 S Address 2:
City: LINDON State: UT
Zip Code: 84042 Country: USA
Status: Active Email:
Director - JOANNE CLINGER
Address 1: 1464 W 40 S Address 2:
City: LINDON State: UT
Zip Code: 84042 Country: USA
Status: Active Email:
President - WILLIAM R SHUPE
Address 1: 3051 W. MAPLE LOOP DR. Address 2:
City: LEHI State: UT
Zip Code: 84043 Country: USA
Status: Active Email:
HERE IS AN OLD statement from the Company?.Regards,CaptD.
Posted by: CuriousJ Date: Tuesday, March 17, 2009 6:24:13 PM
In reply to: None Post # of 2788
To All Concerned:
For the past week or two there have been some misleading and confusing posts on this site regarding the status of our research vessel, R/V BEACON. Understandably, you have questions and I would like to take this opportunity to clarify this recent situation with the facts, and not speculation or rumors. At the present time I am in Alabama, meeting with our Shipping Agent, US Customs and Border Control Agents and various other authorities to determine what the status and condition of the BEACON is after she was removed from port, dry-docked, vandalized and abandoned by the Capt and Co-Capt.
RSOPS/ORRV was not aware of these events until after the fact, and at that time our management team IMMEDIATELY traveled to Bayou LaBatre to assess the situation and “clean up the mess” created by wreckless individuals no longer associated with RSOPS/ORRV. We had no idea the extent of damage and vandalism that had occurred in our absence until we arrived on board, and to say the least, we were appalled.
All of the major equipment had been removed from the ship and hidden in various locations throughout Southern Alabama. These items as well as the blowers and Boston Whaler were only returned after US Customs threatened to arrest those involved.
As you can see from the pictures below, the blowers are now back with the ship. They were on the deck after its return from Ecuador, but were taken off by the Capt and Co-Capt in direct violation of the orders from authorities to not remove ANYTHING from the ship until she cleared customs. They have since been returned and are now lying beside her in the shipyard in Bayou LaBatre, AL. We have also confirmed after inspecting the ship ourselves, that the major equipment is back on board with the exception of the items listed below.
The following pictures are also very telling as to the extent of the damage she has incurred while in the charge of the Capt and Co-Capt.
1) The computer room has been ransacked and the computer system is missing and as of this time has yet to be recovered (see below).
2) The condition of the back deck of the BEACON can be liked to a garbage dump. The area where the blowers once were is now covered in garbage, and misc. debris strewn all over the place (see below).
3) The Boston Whaler has since been returned to the deck of the BEACON, but the motor housing is now damaged (see below).
4) There are other various items still missing from the BEACON:
A) The locked medicine cabinet from the wheel house. This cabinet contained various narcotics for emergency situations at sea such as morphine, epinephrine, etc. The BEACON obtained these medications legally before she sailed to Ecuador over 1 yr ago. As you can see from the picture, the cabinet was removed from the wall. The only person who had access (the only key) to this was the Capt. This is a very serious matter and we have notified the proper authorities.
B) There is a high-definition still-camera as well as a high-def video camera and other electronic equipment missing.
The computer room before….
And now…
The back deck of the R/V BEACON before.
And now…
The damaged Boston Whaler motor housing
Wall where medicine cabinet was located.
Blowers on the ground next to BEACON
The top deck of the BEACON
There are pending legal actions involved in this matter, so for that reason I cannot comment any further at this time. I will continue to update as I am legally allowed.
We fully anticipate having this current situation rectified in the very near future.
Scott Heimdal
President, RS Operations
I did ask to be 'notified' by e-mail if there was to be a auction, I may want to bid. I heard Mr.H. may want to bid too.
News for 'HTDS' - (Hard To Treat Diseases (HTDS.PK) Stem Cells and Regenerative Medicine)
PIRAN, Slovenia/BELGRADE, Serbia, Sept 01, 2009 /PRNewswire-FirstCall via
COMTEX/ -- Hard To Treat Diseases (HTDS.PK) financed the participation of Dr.
Ivana Gadjanski in the International Summer School for Stem Cells and
Regenerative Medicine held in Piran, Slovenia (21-29. Aug 2009) where a number
of eminent speakers presented their work. Among them were Dr. Stephen Minger
from King's College, London; Dr. Smadar Cohen from Ben-Gurion University of the
Negev, Israel; Dr. Thomas Ekstrom from Karolinska Institute, Stockholm, Sweden;
Dr. Zoran Ivanovic from EFS, Bordeaux, France; Dr. Dasa Cziskova from Institute
of Neurobiology, Kosice, Slovakia, Dr. Tanja Dominko and Dr. Raymond L. Page
from Worcester Polytechnic Institute, USA, Dr. Darja Marolt from Columbia
University, USA. Several main topics were discussed: stem cell sources most
suitable for clinical application, ethical issues related to stem cell use,
obstacles of stem cell therapy (e.g. teratoma formation), future clinical trials
(the most interest evokes the FDA-approved world's first human clinical trial of
an embryonic stem cell-based therapy for acute spinal cord injury which will be
perfomed by Geron using their human embrionic stem cell-derived oligodendrocytes
GRNOPC1. The Investigational New Drug Application is currently on clinical hold
by the FDA pending the agency's review of new nonclinical animal study data
submitted by the company. More information availaible from
http://www.geron.com/patients/clinicaltrials/hESC.aspx). Also more technical
issues were discussed, e.g. types of biomaterials used for scaffolds, types of
bioreactors for growing cells, protocols for cell isolation from various
tissues, ways of inducing pluripotency in somatic stem cells (producing iPS),
using umbilical cord blood as a source of stem cells. Very promising are
adipose-derived stem cells (APC), where first reports are available on the in
vivo bone formation and bone augmentation using APC. This type of stem cells
raises the least ethical issues and might hold the highest potential for
clinical application. However, the takehome message of the whole symposium was
that the major task should be to stimulate endogenous potential for repair
rather than to force usage of stem cell therapy per se.
The company intends to provide further updates on a timely basis.
Safe Harbor Statement
TALKING TO SOME-ONE 'in-the-know' about BOAT STORAGE.
The yard master, at A boat yard tells me: IF, YOU DON'T PAY YOUR BILLS IN A REASONABLE TIME, a 'filing' with the court WILL follow.!. And the boat 'MAY BE AT AUCTION' sold for the bills and fees from the yard and 'court fees'.Regards,CaptD.
I think they call it "ABANDON" property.
AS A 'GOOD' deed, I'm going back to Bayou LaBatre and take some pictures, again. I will up-date.. Regards,CaptD. I just want to see HOW LONG DOES IT TAKE TO pay the bill and get the boat wet. A 'haul-out' and a 'storage' bill so far.(I heard the bill was sum 25K)...So????..If, I got a MILLION dollar private ?placement? months ago? I would get MY boat fixed and go to work..
Post Unavailable
Additional Information
Post Unavailable
Additional Information
It has been a long time and I've waited this long, I'll hang around to see what MONA looks like in 2010, I've made it through 2008 ....
FYI: this week I will attempt to SELL all ORRV shares. I'm out of this one soon and totally. Regards,CaptD.
Their Web-site says 'American-Flaged', this shows PANAMA-Flaged??..It does say PANAMA under Beacon on the ship itself though? go figure??So many different statements by different personal and none confirm each-other.